Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
International Seaways
INSW
$4.71B
| $3.05M | ﹤0.01% |
62,737
+3,568
| +6% | +$176K |
|
2602
ProPetro Holding
PUMP
$1.42B
| $3.04M | ﹤0.01% |
319,772
+31,449
| +11% | +$273K |
|
2603
Crane NXT
CXT
$2.96B
| $3.04M | ﹤0.01% |
64,606
-5,632
| -8% | -$333K |
|
2604
Corvus Pharmaceuticals
CRVS
$1.27B
| $3.04M | ﹤0.01% |
394,766
+85,614
| +28% | +$675K |
|
|
ETHA
2605
CALL
iShares Ethereum Trust ETF
ETHA
$5.56B
| $3.03M | ﹤0.01% |
135,300
-164,700
| -55% | -$4.31M |
|
2606
Graphic Packaging
GPK
$3.46B
| $3.03M | ﹤0.01% |
201,385
-114,120
| -36% | -$1.88M |
|
2607
Origin Bancorp
OBK
$1.67B
| $3.03M | ﹤0.01% |
80,588
+14,622
| +22% | +$524K |
|
2608
Procept Biorobotics
PRCT
$1.26B
| $3.03M | ﹤0.01% |
96,329
+18,658
| +24% | +$619K |
|
2609
Buckle
BKE
$2.33B
| $3.03M | ﹤0.01% |
56,692
-9,808
| -15% | -$547K |
|
2610
PUT
Clorox
CLX
$12.8B
| $3.02M | ﹤0.01% |
+30,000
| New | +$3.26M |
|
2611
MasterBrand
MBC
$1.87B
| $3.02M | ﹤0.01% |
273,380
+50,536
| +23% | +$592K |
|
2612
Skyward Specialty Insurance
SKWD
$2.44B
| $3.01M | ﹤0.01% |
58,880
+7,376
| +14% | +$355K |
|
2613
Boston Beer
SAM
$1.89B
| $3M | ﹤0.01% |
15,398
-1,699
| -10% | -$350K |
|
2614
US Treasury 6 Month Bill ETF
XBIL
$745M
| $3M | ﹤0.01% |
+60,000
| New | +$3.01M |
|
|
EA
2615
PUT
DELISTED
Electronic Arts
EA
| $3M | ﹤0.01% |
14,700
| – | – |
|
2616
CALL
Boston Scientific
BSX
$74.9B
| $3M | ﹤0.01% |
31,500
| – | – |
|
2617
Artivion
AORT
$1.39B
| $3M | ﹤0.01% |
65,703
+11,087
| +20% | +$494K |
|
2618
Element Solutions
ESI
$9.51B
| $2.99M | ﹤0.01% |
119,784
+8,487
| +8% | +$220K |
|
2619
Intuitive Machines
LUNR
$2.82B
| $2.99M | ﹤0.01% |
184,333
+30,238
| +20% | +$350K |
|
2620
Horace Mann Educators
HMN
$2.09B
| $2.98M | ﹤0.01% |
64,515
+6,888
| +12% | +$312K |
|
2621
PUT
Bank OZK
OZK
$5.69B
| $2.97M | ﹤0.01% |
+64,600
| New | +$3.02M |
|
2622
Aurinia Pharmaceuticals
AUPH
$2.02B
| $2.97M | ﹤0.01% |
186,140
+14,540
| +8% | +$206K |
|
|
ALEX
2623
DELISTED
Alexander & Baldwin
ALEX
| $2.97M | ﹤0.01% |
143,786
-25,620
| -15% | -$445K |
|
2624
Photronics
PLAB
$1.97B
| $2.96M | ﹤0.01% |
92,618
+6,890
| +8% | +$178K |
|
2625
Coastal Financial
CCB
$754M
| $2.95M | ﹤0.01% |
25,781
+5,920
| +30% | +$646K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.